1. Home
  2. AAT vs LTGO Comparison

AAT vs LTGO Comparison

Compare AAT & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Assets Trust Inc.

AAT

American Assets Trust Inc.

HOLD

Current Price

$22.77

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$19.49

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AAT
LTGO
Founded
1967
N/A
Country
United States
United States
Employees
208
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2010
2026

Fundamental Metrics

Financial Performance
Metric
AAT
LTGO
Price
$22.77
$19.49
Analyst Decision
Sell
Analyst Count
2
0
Target Price
$19.50
N/A
AVG Volume (30 Days)
388.5K
581.8K
Earning Date
04-28-2026
N/A
Dividend Yield
6.65%
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$436,204,000.00
N/A
Revenue This Year
$4.33
N/A
Revenue Next Year
$0.22
N/A
P/E Ratio
$287.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.72
$17.22
52 Week High
$25.97
$20.50

Technical Indicators

Market Signals
Indicator
AAT
LTGO
Relative Strength Index (RSI) 39.12 64.63
Support Level $18.23 N/A
Resistance Level $25.76 N/A
Average True Range (ATR) 0.52 1.48
MACD -0.10 0.14
Stochastic Oscillator 23.43 56.10

Price Performance

Historical Comparison
AAT
LTGO

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: